{
    "Trade/Device Name(s)": [
        "Dexcom G6 Glucose Program Continuous Glucose Monitoring System",
        "Dexcom Glucose Program System"
    ],
    "Submitter Information": "Dexcom, Inc.",
    "510(k) Number": "K182041",
    "Predicate Device Reference 510(k) Number(s)": [],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "QDK"
    ],
    "Summary Letter Date": "July 26, 2018",
    "Summary Letter Received Date": "July 30, 2018",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 862.1355"
    ],
    "Regulation Name(s)": [
        "Integrated continuous glucose monitoring system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Interstitial fluid"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Dexcom G6 Glucose Program sensor/applicator",
        "Dexcom transmitter",
        "Mobile application (app)"
    ],
    "Method(s)/Technology(ies)": [
        "Amperometric measurement",
        "Glucose oxidase chemical reaction"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "System",
        "Sensor",
        "Transmitter",
        "Application",
        "Accessory"
    ],
    "Document Summary": "FDA 510(k) summary for Dexcom G6 Glucose Program Continuous Glucose Monitoring System for real-time management of diabetes via continuous glucose monitoring",
    "Indications for Use Summary": "Real-time, continuous glucose monitoring system indicated for diabetes management in persons age 2 years and older, intended to replace fingerstick blood glucose testing for diabetes treatment decisions and aid in detection of hypo- and hyperglycemia, can be used alone or with digitally connected devices",
    "fda_folder": "Clinical Chemistry"
}